Global Anti-Hypertensive Drugs Market By Type (Diuretics, ACE inhibitors, ARBs, Calcium Channel Blockers, Beta - Adrenergic blocker, Alpha - Adrenergic blocker, Central Sympatholyics, Renin inhibitors, Vasodilators): Market Growth, Future Prospects And Competitive Analysis, 2016 - 2023

Hypertension is most commonly observed chronic disease, which causes elevation in systolic and diastolic blood pressure, which in long term is high risk factor for coronary artery disease, heart failure, stroke etc.. The anti-hypertensive drugs are used to control the blood pressure. The antihypertensive drugs market major drivers is the prevalence of the chronic disease along with growing population and altering lifestyle, with increase in awareness of treatment, new drug approval and healthcare expenditure.

The report titled “Global Anti-Hypertensive Drugs Market - Growth, Share, Opportunities and Competitive Analysis, 2016–2023” offers strategic insights into the overall anti-hypertensive drugs market along with the market size and estimates for the duration 2016 to 2023. The said research study covers in-depth analysis of multiple market segments based on type of drug class and different geographical region. The Drug class type segment studied for analyzing the overall anti-hypertensive drugs market is majorly segmented into Diuretics, Angiotensin receptor blockers (ARBs), Angiotensin converting enzyme (ACE) inhibitors, Beta blockers, Alpha blockers, Calcium channel blockers, Renin inhibitors and Vasodilators.

In order to help strategic decision makers, the report also includes competitive profiling of the leading players in anti-hypertensive drugs market, pipeline analysis, attractive investment proposition market positioning of key manufacturers sections. Other in-depth analysis provided in the report includes:

Geographically, the global anti-hypertensive drugs market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of LATAM
  • Middle East and Africa

Market size and forecast for these regional and country level markets are presented in this study for the period 2013-2023. Market growth rates for the forecast period 2016-2023 are also included in this report, considering 2015 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global anti-hypertensive drugs market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global anti-hypertensive drugs market. This report concludes with company profiles section that highlights major information about the key players engaged in global anti-hypertensive drugs market. In-depth competitive environment analysis and historical years (2013 & 2014) market size data are also provided in the report.

Thus, the research study provides a holistic view of the global anti-hypertensive drug market, offering market size and estimates for the period from 2016 to 2023, keeping in mind the above-mentioned factors.


Anti-Hypertensive Drugs Market

For the purpose of this study, the Global Anti-Hypertensive Drugs Market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Anti-Hypertensive Drugs Market

The global anti-hypertensive drugs market is bifurcated into four regions: North America, Europe, Asia-Pacific, Latin America and Middle East. The global Anti-Hypertensive Drug market is dominated by the North America region occupying the major market. The major contributor in this region is US due to factors such as the prevalence of hypertension, rise in geriatric population, upcoming new drug in pipeline and use of combination therapy. Europe is next followed up market with major contributor being UK, Germany, France, Italy and Spain. According to research studies, with rise in population of Europe, there is considerable increase in number of people suffering from hypertension, therefore to address the unmet need for appropriate health care planning and expenditure are the major driving factors for the European market. The Asia-pacific is the lucrative market, with major contributors being Japan, India and China. Asia-Pacific carries almost half of the world cardiovascular burden, in which upto 66% of subtype of CVD contribute to hypertension due to increase in urbanization and adoption of unhealthy lifestyle and food. Thus developed countries dominates the market of hypertensive, emerging economies with growing population and increasing government spending on health care is lucrative market.

Choose License Type
Published Date:  Dec 2016
Category:  Pharmaceuticals
Report ID:   58287
Report Format:   PDF
Pages:   120
Rating:    4.1 (50)
Connect With Us
+1-408-641-3282
24/7 Research Support